



## Michigan Quality Improvement Consortium Clinical Practice Guideline Update Alert

Guideline: [Diagnosis and Management of Adults with Chronic Kidney Disease](#)

Released: November 2020

This alert provides a summary of only the recommendations which were updated. Refer to the complete guideline for all recommendations and level of evidence.

### Updated recommendations include:

#### **Adults with CKD**

##### **Core Principles of Treatment**

- Review medications for dose adjustment, drug interactions, adverse effects, and therapeutic levels. Modify dosage for renal cleared medications, e.g., Metformin, antibiotics. Avoid NSAIDs if CKD Stage 3, 4 or 5, or micro- or macroalbuminuria.
- Salt restriction for patients with CKD and hypertension (1500 mg/d or decrease by 1000 mg/d).

##### **Clinical Plan based on CKD stage and albuminuria**

*Refer to guideline for all CKD stages.*

- Stage 2 (GFR 60-89): Consider nephrology referral if GFR decline > 5mL/min/yr, or if macroalbuminuria.
- Stage 3a (GFR 45-59): Nephrology referral if anemic or abnormal PTH, VitD, Ca, or phosphorus. Avoid contrast, if possible. Avoid NSAIDs. Low-dose ASA allowed. Avoid contrast (iodinated and gadolinium-based) in Stage 3, 4, or 5.